Navigation Links
Neuralstem Grants Licenses For Central Nervous System Therapy Surgical Devices To Cedars-Sinai Medical Center
Date:2/20/2013

ROCKVILLE, Md., Feb. 20, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that it has granted licenses to intellectual property surrounding its spinal cord delivery platform, floating cannula, and method for delivering therapeutic agents to the spinal cord to Cedars-Sinai Medical Center, a non-profit academic medical center located in Los Angeles, CA. The license agreements grant Cedars-Sinai Medical Center the non-exclusive right to use the licensed intellectual property in academic research. This is the second group of licenses announced by Neuralstem for these technologies. The financial terms of the agreement were not disclosed. Neuralstem holds the exclusive worldwide licenses to the platform and cannula technologies. 

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO)

The platform and cannula have been used since 2010 in a Phase I ALS trial, sponsored by Neuralstem and recently completed at Emory University, covering the delivery of Neuralstem's NSI-566 neural stem cells into the spinal cords of patients with amyotrophic lateral sclerosis (ALS or Lou Gehrig 's disease). Neuralstem recently received FDA approval to commence a Phase I trial in chronic spinal cord injury using the platform and cannula technologies.

"This second set of licenses for our devices further demonstrates the growing acceptance of intraspinal delivery of therapeutics, once thought impossible, in the treatment of spinal cord conditions and diseases," said Richard Garr , Neuralstem's President and CEO. "We have shown that it can be done safely in our ALS trial in 15 patients, and 18 procedures, in which three patients successfully returned for second transplants. We plan to continue our licensing program to industry and academia as they begin to explo
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neuralstem Updates ALS Stem Cell Trial Progress
2. Sixteenth Patient Dosed In Neuralstem ALS Stem Cell Trial
3. First Patients Dosed in Ib Phase of Neuralstems NSI-189 Trial in Major Depressive Disorder
4. Seventeenth Patient Dosed in Neuralstem ALS Stem Cell Trial
5. Neuralstem Announces Exercise Of Entire Over-Allotment Option By Aegis Capital Corp.
6. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
7. Neuralstem Announces Proposed Public Offering
8. Neuralstem to Raise $7.0 Million in Registered Direct Offering
9. Neuralstem President And CEO To Present At BIO CEO & Investor Conference 2013
10. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
11. Community Foundation Announces $2.6 Million In Grants From Centinela Medical Funds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014  NeuroSigma, Inc. (NeuroSigma), ... focused on commercialization of its non-invasive Monarch ... and neuropsychiatric disorders, today announced that enrollment has begun ... nerve stimulation (eTNS) as adjunctive therapy for the treatment ... being conducted at the Olive View-UCLA Medical Center in ...
(Date:7/22/2014)... York , July 22, 2014 ... Partnerschaft für umfassenden Schutz von Pharmazeuten ... Österreich    Equashield ( ... Transfersystemen (Closed System Transfer Devices, CSTDs) für gefährliche ... einen Vertriebshändler und Hersteller von medizinischen ...
(Date:7/21/2014)... McCord Research, Inc. was recently granted ... This patent describes a method for accelerating wound ... inventor, Dr. McCord, this method includes administering or ... composition of an effective amount of hydroxytyrosol and ... such that the administration of the combination reduces ...
Breaking Medicine Technology:Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2US Patent Office Grants McCord Research Endothelial Cell Treatment Patent 2
... well-tolerated with signs of durable,disease control in advanced ... /PRNewswire-FirstCall/ -- IDM,Pharma, Inc. today presented preliminary results ... trial (DC-MEL-202). The,results showed that UVIDEM was well ... response in patients with,progressive metastatic melanoma. , The ...
... trial presented at ENDO 2007 , ,- Regulatory approvals ... recruitment in Europe , ,MONTREAL, QUEBEC -- (MARKET WIRE) ... that 26-week data from,its first Phase 3 study testing ... ENDO, the 89th,annual meeting of the Endocrine Society. The ...
Cached Medicine Technology:IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 2IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 3IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 4IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 5Theratechnologies: TH9507 Phase 3 Clinical Update 2Theratechnologies: TH9507 Phase 3 Clinical Update 3
(Date:7/22/2014)... July 22, 2014 The Pennsylvania ... ) in the Philadelphia Court of ... punitive damages in cases alleging the medication caused ... Liebhard LLP reports. In an Order dated July ... plaintiffs’ request to certify the matter for an ...
(Date:7/22/2014)... The park is the heart of a community. ... made a recent investment in outdoor recreation and ... playground equipment from American Parks Company™. , The community ... is a 475-unit community that was established in the ... a tropical paradise with lush shade trees, green-edged walking ...
(Date:7/22/2014)... of the largest studies ever conducted into the genetic ... sites on chromosomes that harbor inherited genes tied to ... of researchers, now bring the total number of common ... Although these schizophrenia-associated genes aren,t specific enough to ... or will not develop the illness, researchers say they ...
(Date:7/22/2014)... school lacrosse players are facing an increasing number of ... study finds. Although the most common injuries are ... researchers report. They note a better understanding of why ... to protect student athletes. "Concern over concussions in ... learn more about these injuries," said study co-author Dawn ...
(Date:7/22/2014)... CarePoint Health is pleased to announce that Dr. ... the medical staff at Bayonne Medical Center. The election marks ... voted on by the physicians on staff. The office of ... to the administration at Bayonne Medical Center. Dr. Levine is ... to make the Medical Center the best it can be ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 2Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 3Health News:Gene Discoveries Could Shed New Light on Schizophrenia 2Health News:Injuries on the Increase in High School Lacrosse, Study Shows 2Health News:Injuries on the Increase in High School Lacrosse, Study Shows 3Health News:Dr. Howard Levine Elected President of the Medical Staff at Bayonne Medical Center 2
... Medical Innovations, Inc. (Amex: IMA ), a ... solutions, announced today that it will attend the upcoming ... 15, 2009 at the Westin St. Francis Hotel in ... Jon Russell, Vice President, Finance, will attend. Mr. ...
... Corporation (Nasdaq: BPUR ) announced today that ... stating that NASDAQ has again suspended enforcement of its ... listing, thereby extending the Company,s time in which to ... to resume on Monday, April 20, 2009. The Company ...
... Executive with Proven Ability to Develop Companies into ... Growth OpportunitiesFORT LAUDERDALE, Fla., Dec. 30 eDiets.com, ... provider of convenient at-home diet, fitness and healthy ... the company,s new President and CEO, effective immediately. ...
... didn,t halt women,s risk of developing disease , , TUESDAY, ... the supposed cancer-fighting powers of vitamins C and E, ... don,t prevent the disease in women. , And another ... new study found. , , "Simply taking antioxidant supplements ...
... had cancer as well as idiopathic pulmonary fibrosis, study finds ... in a gene previously found to help protect the lungs ... some inherited cases of a lethal lung disease affecting older ... the SFTPA2 gene have been found in families ...
... of adults and 19 percent of children taking chemotherapy drugs ... dose or experienced other mistakes involving their medications, according to ... professor of pediatrics at the University of Massachusetts Medical School, ... Journal of Clinical Oncology . , "As cancer care ...
Cached Medicine News:Health News:Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 13, 2009 2Health News:Biopure Receives Extension of Time to Regain NASDAQ Listing Compliance 2Health News:eDiets.com(R) Appoints Kevin N. McGrath as President and CEO 2Health News:eDiets.com(R) Appoints Kevin N. McGrath as President and CEO 3Health News:Vitamins Fail to Prevent Cancer: Study 2Health News:Vitamins Fail to Prevent Cancer: Study 3Health News:Gene Mutation Tied to Inherited Fatal Lung Disease 2Health News:Errors involving medications common in outpatient cancer treatment 2
... practical, comfortable chair for examination ... height is adjustable from 540 ... use of an independent foot ... through 360 and incorporates a ...
... Halogen HPX Streak Retinoscope ... handle and provides 40% ... conventional scopes and maintains ... which greatly enhances illumination ...
Sandown chair, with hydraulic lift, sliding headrest and armrests with glides. Black vinyl....
3.5v Halogen HPX Spot Retinoscope provides 40% more light output than conventional scopes and maintains a consistent output level which greatly enhances illumination and produces the sharpest retina...
Medicine Products: